Amniotics AB (OSTO:AMNI) Debt-to-Equity : 0.00 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Amniotics AB Debt-to-Equity?

Amniotics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was kr0.00 Mil. Amniotics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was kr0.00 Mil. Amniotics AB's Total Stockholders Equity for the quarter that ended in Sep. 2023 was kr2.36 Mil. Amniotics AB's debt to equity for the quarter that ended in Sep. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Amniotics AB's Debt-to-Equity or its related term are showing as below:

OSTO:AMNI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 10.16
Current: 6.38

During the past 4 years, the highest Debt-to-Equity Ratio of Amniotics AB was 10.16. The lowest was 0.01. And the median was 0.02.

OSTO:AMNI's Debt-to-Equity is ranked worse than
97.96% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs OSTO:AMNI: 6.38

Amniotics AB Debt-to-Equity Historical Data

The historical data trend for Amniotics AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amniotics AB Debt-to-Equity Chart

Amniotics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.03

0.02

10.16

Amniotics AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial									-	-	10.16	-	-

Competitive Comparison of Amniotics AB's Debt-to-Equity

For the Biotechnology subindustry, Amniotics AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amniotics AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amniotics AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Amniotics AB's Debt-to-Equity falls into.

Amniotics AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Amniotics AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.067	+	0)	/	1.483
	=	10.16

Amniotics AB's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	2.363
	=	0.00

Amniotics AB (OSTO:AMNI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Amniotics AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Amniotics AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Amniotics AB (OSTO:AMNI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amniotics AB (OSTO:AMNI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

66J:Germany

Address

Scheelevagen 2, Lund, SWE, 223 63

Website

https://www.amniotics.com

Amniotics AB is a biopharma company focusing on mesenchymal stem cells from amniotic fluid. It provides a novel platform for the production of medically superior mesenchymal stem cells including ethical and medically sound bio-banking opportunities for the newborn.